Evidence map›Paper›PMID 39145385›Full record

ArticleCirculation research2024

Microparticle Mediated Delivery of Apelin Improves Heart Function in Post Myocardial Infarction Mice.

Ling Tang, Huiliang Qiu, Bing Xu, Yajuan Su, Verah Nyarige, Pengsheng Li, Houjia Chen, Brady Killham, Jun Liao, Henderson Adam and 6 more

Abstract read
In one paragraph

Article in Circulation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Signaling Pathways and Therapeutic Approaches in Post-Myocardial Infarction Fibrosis.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Review
  12. The Impact of the Apelinergic System on the Cardiovascular System.International journal of molecular sciences · 2025
    Review
  13. Review
  14. Article
  15. Polymeric Nanomaterials for Atherosclerosis Diagnosis and Treatment.Polymer science & technology (Washington, D.C.) · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Ling Tang *Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale (L.T., H.Q., B.X., V.N., P.L., H.A., A. Yang, A. Yu, M.J., W.Z.).ORCID 0000-0002-5378-9442
Huiliang Qiu *Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale (L.T., H.Q., B.X., V.N., P.L., H.A., A. Yang, A. Yu, M.J., W.Z.).ORCID 0000-0001-8625-8974
Bing Xu *Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale (L.T., H.Q., B.X., V.N., P.L., H.A., A. Yang, A. Yu, M.J., W.Z.).
Yajuan Su *Department of Surgery-Transplant and Mary and Dick Holland Regenerative Medicine Program, University of Nebraska Medical Center, Omaha (Y.S., J.X.).ORCID 0000-0003-2418-824X
Verah NyarigeDepartment of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale (L.T., H.Q., B.X., V.N., P.L., H.A., A. Yang, A. Yu, M.J., W.Z.).ORCID 0000-0001-6707-3384
Pengsheng LiDepartment of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale (L.T., H.Q., B.X., V.N., P.L., H.A., A. Yang, A. Yu, M.J., W.Z.).ORCID 0000-0001-8867-1527
Houjia ChenDepartment of Bioengineering, University of Texas at Arlington (H.C., B.K., J.L.).
Brady KillhamDepartment of Bioengineering, University of Texas at Arlington (H.C., B.K., J.L.).
Jun LiaoDepartment of Bioengineering, University of Texas at Arlington (H.C., B.K., J.L.).ORCID 0000-0003-1049-5783
Henderson AdamDepartment of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale (L.T., H.Q., B.X., V.N., P.L., H.A., A. Yang, A. Yu, M.J., W.Z.).ORCID 0000-0003-4792-9338
Aaron YangDepartment of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale (L.T., H.Q., B.X., V.N., P.L., H.A., A. Yang, A. Yu, M.J., W.Z.).ORCID 0000-0002-6041-3654
Alexander YuDepartment of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale (L.T., H.Q., B.X., V.N., P.L., H.A., A. Yang, A. Yu, M.J., W.Z.).ORCID 0000-0002-7246-2269
Michelle JangDepartment of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale (L.T., H.Q., B.X., V.N., P.L., H.A., A. Yang, A. Yu, M.J., W.Z.).ORCID 0009-0004-7888-1044
Michael RubartDepartment of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis (M.R.).ORCID 0000-0002-7386-6943
Jingwei XieDepartment of Surgery-Transplant and Mary and Dick Holland Regenerative Medicine Program, University of Nebraska Medical Center, Omaha (Y.S., J.X.).ORCID 0000-0002-8126-1397
Wuqiang ZhuDepartment of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale (L.T., H.Q., B.X., V.N., P.L., H.A., A. Yang, A. Yu, M.J., W.Z.).ORCID 0000-0001-5217-7789

Funding

Cardiomyocyte Non-autonomous Factors and Cardiac Regeneration in Large MammalsR01HL156855 · NHLBI · MAYO CLINIC ARIZONA · PI Wuqiang Zhu · 2022 to 2026
$3.3M
Strategies to Enhance Engineered Heart Tissue Based Myocardial RepairR01HL162747 · NHLBI · MAYO CLINIC ARIZONA · PI Jingwei Xie, Wuqiang Zhu · 2023 to 2026
$2.9M
Electrically Conductive Stem Cell Derived MicroEngineered Heart Tissue for Regeneration of Injured MyocardiumR01HL172784 · NHLBI · MAYO CLINIC ARIZONA · PI Mehdi Nikkhah, Wuqiang Zhu · 2024 to 2026
$2.0M
Myocardial Repair with a Novel Engineered Cardiac Muscle PatchR01HL142627 · NHLBI · MAYO CLINIC ARIZONA · PI ZHU, WUQIANG · 2019 to 2022
$1.7M
A Controlled Septal Ablation for Inoperable Hypertrophic CardiomyopathyR15HL159599 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI LIAO, JUN · 2022 to 2022
$433k
Myocardial Repair with a Novel Engineered Cardiac Muscle PatchR56HL142627 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHU, WUQIANG · 2018 to 2018
$371k
NHLBI NIH HHS R01 HL142627NHLBI NIH HHS R01 HL156855NHLBI NIH HHS R01 HL162747NHLBI NIH HHS R01 HL172784NHLBI NIH HHS R15 HL159599NHLBI NIH HHS R56 HL142627
6 · The paper itself

Abstract

backgroundApelin is an endogenous prepropeptide that regulates cardiac homeostasis and various physiological processes. Intravenous injection has been shown to improve cardiac contractility in patients with heart failure. However, its short half-life prevents studying its impact on left ventricular remodeling in the long term. Here, we aim to study whether microparticle-mediated slow release of apelin improves heart function and left ventricular remodeling in mice with myocardial infarction (MI).

methodsA cardiac patch was fabricated by embedding apelin-containing microparticles in a fibrin gel scaffold. MI was induced via permanent ligation of the left anterior descending coronary artery in adult C57BL/6J mice followed by epicardial patch placement immediately after (acute MI) or 28 days (chronic MI) post-MI. Four groups were included in this study, namely sham, MI, MI plus empty microparticle-embedded patch treatment, and MI plus apelin-containing microparticle-embedded patch treatment. Cardiac function was assessed by transthoracic echocardiography. Cardiomyocyte morphology, apoptosis, and cardiac fibrosis were evaluated by histology. Cardioprotective pathways were determined by RNA sequencing, quantitative polymerase chain reaction, and Western blot.

resultsThe level of endogenous apelin was largely reduced in the first 7 days after MI induction and it was normalized by day 28. Apelin-13 encapsulated in poly(lactic-co-glycolic acid) microparticles displayed a sustained release pattern for up to 28 days. Treatment with apelin-containing microparticle-embedded patch inhibited cardiac hypertrophy and reduced scar size in both acute and chronic MI models, which is associated with improved cardiac function. Data from cellular and molecular analyses showed that apelin inhibits the activation and proliferation of cardiac fibroblasts by preventing transforming growth factor-β-mediated activation of Smad2/3 (supporessor of mothers against decapentaplegic 2/3) and downstream profibrotic gene expression.

conclusionsPoly(lactic-co-glycolic acid) microparticles prolonged the apelin release time in the mouse hearts. Epicardial delivery of the apelin-containing microparticle-embedded patch protects mice from both acute and chronic MI-induced cardiac dysfunction, inhibits cardiac fibrosis, and improves left ventricular remodeling.

Indexed as

ApelinMyocardial InfarctionAnimalsApoptosisDisease Models, AnimalFibrosisMaleMiceMice, Inbred C57BLMyocytes, CardiacVentricular Function, LeftVentricular RemodelingApelinApln protein, mouseanimalsfibroblastsheart failuremicemyocardial infarction

Identifiers

PMID39145385
PMCPMC11392624

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.